Literature DB >> 11181927

Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity.

M R Brandt1, M S Furness, N K Mello, K C Rice, S S Negus.   

Abstract

The effects of SNC80 and other structurally related delta-opioid receptor agonists were assessed under conditions of chemically induced hypersensitivity to thermal stimuli in four rhesus monkeys. The shaved tail of each monkey was exposed to warm water (38, 42, 46, and 50 degrees C), and the tail-withdrawal latency from each temperature was recorded. The effects of drugs on the temperature that produced a 10-s tail-withdrawal latency (the T(10) value) were examined. Capsaicin (0.01-0.32 mg) injected into the tail of monkeys dose dependently decreased the T(10), indicating that capsaicin increased sensitivity to thermal stimuli. A dose of 0.1 mg of capsaicin decreased the T(10) from 48.0 to 42.1 degrees C (a -5.9 degrees C change) 15 min after injection. SNC80 (1.0-10.0 mg/kg s.c.) dose dependently blocked the capsaicin-induced decrease in the T(10), and 10.0 mg/kg SNC80 fully blocked the effects of capsaicin. The delta-selective antagonist naltrindole (0.1-1.0 mg/kg) dose dependently antagonized the effects of SNC80, whereas a mu-selective dose of the opioid antagonist quadazocine (0.1 mg/kg) did not. Two other delta-selective agonists, SNC162 (1.0-10.0 mg/kg) and SNC243A (1.0-10.0 mg/kg), also dose dependently blocked capsaicin-induced thermal hypersensitivity. In contrast, neither SNC67 (10.0 mg/kg), which is the (-)-enantiomer of SNC80, nor the nonsteroidal anti-inflammatory drug (NSAID) ketorolac (1.0-10.0 mg/kg) modified the effects of capsaicin. SNC80 was also effective in reversing thermal hypersensitivity induced by prostaglandin E(2) (0.0158 mg) and Freund's complete adjuvant (10% concentration). These findings suggest that delta-agonists have antinociceptive effects in primates under conditions of chemically induced thermal hypersensitivity and might be effective under a broader range of conditions than clinically available NSAIDs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181927

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

Review 1.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys.

Authors:  Ingela Danielsson; Maciej Gasior; Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

3.  Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

Authors:  Matthew L Banks; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2010-08-03       Impact factor: 3.533

4.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

5.  Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Nancy K Mello; Kenner C Rice; John E Folk; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2006-07-05       Impact factor: 4.432

6.  Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-07-13       Impact factor: 4.030

7.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

8.  Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Nicholas P Walker; John E Folk; Kenner C Rice; Philip S Portoghese; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

9.  Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain.

Authors:  Devki D Sukhtankar; Heeseung Lee; Kenner C Rice; Mei-Chuan Ko
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

10.  Pharmacological Properties of δ-Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve.

Authors:  Isaac J Dripps; Ruizhuo Chen; Amanda M Shafer; Kathryn E Livingston; Alexander Disney; Stephen M Husbands; John R Traynor; Kenner C Rice; Emily M Jutkiewicz
Journal:  J Pharmacol Exp Ther       Date:  2020-05-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.